BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bio Based Press - ECPv5.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bio Based Press
X-ORIGINAL-URL:https://www.biobasedpress.eu
X-WR-CALDESC:Events for Bio Based Press
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20190415T080000
DTEND;TZID=Europe/Paris:20190416T170000
DTSTAMP:20201230T215305
CREATED:20181013T084730Z
LAST-MODIFIED:20181016T092955Z
UID:13710-1555315200-1555434000@www.biobasedpress.eu
SUMMARY:12th European Biosimilars Congress
DESCRIPTION: 12th European Biosimilars Congress 2019 Organizing Committee invites you to attend the largest assemblage of biologics and biosimilars researchers from around the globe during April 15-16\, 2019 at Berlin\, Germany. \nEuropean Biosimilars Congress is a global annual event. This Biosimilars Congress 2019 brings together scientists\, researchers\, business development managers\, CEOs\, directors\, IP Attorneys\, Regulatory Officials and CROs from around the world. The passage of Biosimilars through a decade at Asia finds much requirement for discussion also focusing the Current Challenges in Developing Biosimilars. \nCONFERENCE HIGHLIGHTS \n\nCurrent Challenges in Developing Biosimilars\nChemical and Analytical Strategies for Biosimilars\nIntellectual Property Rights\nBiological Medicine\nEmerging Biosimilars in Therapeutics\nInnovative Clinical Approach in Biosimilars\nRegulatory Updates on Biosimilars\nBiosimilars Development in Markets\nBiosimilars Approval to Biogenerics in Clinical Practice\nBiopharmaceutical Informatics\nConsequences of Brexit on Biosimilars\nBCS and IVIVC Based Biowaivers\nBiosimilars Market and Cost Analysis\nChallenges in Biosimilars Pharmacovigilance\nLegal Issues and BPCI Act\nFormulation Strategies for Follow-on Biologics\nCurrent Agency Expectations for Approval for Biosimilars\nBiosimilars Research Pipeline\nGlobalization of Biosimilars\nDrug Delivery and Development\nMonoclonal Antibody Biosimilars\nUSFDA Approved Biosimilars\n\n  \nHappily invite attendees from Chief Executives\, Directors\, Vice Presidents\, Department Heads\, Leaders and Managers specialising in: \nBiologics/Biotechnology/ Biogenerics\, Legal Affairs\, Pricing and Reimbursement\, Regulatory Compliance\, Preclinical and Clinical Development\, Quality Affairs/ Quality Control\, Biopharmaceuticals\, Intellectual property\, Clinical Immunology\, R&D\, New Product Development and Pharmacovigilance \nFrom Industries Including: \nClinical Immunology\, Immunology\, Drug Safety\, Preclinical Development\, Therapeutic Areas\, Business Development\, Vaccines Development\, Scientific Affairs\, Validation\, Analytical Characterization\, Antibody Discovery\, Oncology\, Infection and Immunity\, Risk Management\, Clinical Program\, Personalized Medicine\, Portfolio Planning\, Regulatory Affairs\, Pharmacovigilance\, Global Strategy and Antibody Engineering \nWebsite Link: https://biosimilars-biologics.pharmaceuticalconferences.com/europe/ \nAbstract Submission Link: https://biosimilars-biologics.pharmaceuticalconferences.com/europe/abstract-submission.php \nRegistration link: https://biosimilars-biologics.pharmaceuticalconferences.com/europe/registration.php \nContact Details: \nJohn Hill \nProgram Manager | Biosimilar conferences 2019 \n47 Churchfield Road\, London\, W3 6AY \nToll Free: +448000148923 \neurobiosimilars@pharmaceuticalconferences.org \neuropeanbiosimilarscongress@gmail.com
URL:https://www.biobasedpress.eu/event/12th-european-biosimilars-congress/
LOCATION:Berlin\, Duitsland
END:VEVENT
END:VCALENDAR